Prevalence of chronic pain with neuropathic characteristics in the general population

By D. Bouhassira, M. Lanteri-Minet, N. Attal, Bernard Laurent, C. Touboul. Pain, 2008

1,655 citations recorded by the source corpus.

Subfields: Neurology, Pharmacology, Physiology

View Paper: https://www.semanticscholar.org/paper/15b94aa93e42455254b2218e0efc25804041d2c8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. G. Moalem-Taylor
2. P. Austin
3. T. S. Jensen
4. Clifford J. Woolf
5. J. Scholz
6. R. Baron
7. Blair H. Smith
8. N. Attal

In Pharmacology

1. G. Moalem-Taylor
2. P. Austin
3. J. Scholz
4. Blair H. Smith
5. T. S. Jensen
6. N. Attal
7. R. Baron
8. Clifford J. Woolf

In Physiology

1. G. Moalem-Taylor
2. P. Austin
3. Clifford J. Woolf
4. R. Baron
5. T. S. Jensen
6. J. Scholz
7. M. Costigan
8. Roger B. Fillingim

Citations in the corpus

• The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. (2010, positive): “However, in about 7% to 18% of the general population (Bouhassira et al., 2008; Toth et al., 2009) pain persists despite injury healing, resulting in a state of chronic neuropathic pain.”
• EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision (2010, background): “Background and objectives Neuropathic pain (NP) may be caused by a lesion or a disease of the somatosensory system [1] and is estimated to afflict as high as 7–8% of the general population in Europe [2,3].”
• Neuropathic pain in the general population: A systematic review of epidemiological studies (2014, background): “Some studies were funded by government, charity, or nonprofit organisations [8,15,21–23,26,30,38]; others had educational grants from industry but no authorship [4,6,7,10,24,35,42]; and the remainder were conducted and/or supported by pharmaceutical industry and had declared authorship [9,13,14,18,1”
• Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). (2014, neutral): “Neuropathic pain is a major public health problem because of its prevalence (affecting up to 6–7% of the general population (Torrance et al., 2006; Bouhassira et al., 2008) and because of the limited efficacy of current therapies: only 30–40% of patients declare they receive satisfactory (>50”
• Sex, Gender, and Pain: A Review of Recent Clinical and Experimental Findings (2009, background): “Until recently, therewas little epidemiological data on chronic neuropathic pain at the population level because of the lack of an appropriate assessment instrument to identify the characteristics of neuropathic pain in community samples.(44) However, studies have examined sex differences in the epi”
• Neuropathic Pain (2009, background): “Spontaneous pain may arise both from ectopic activity in nociceptors (Bostock et al. 2005) and from low-threshold large myelinated afferents (Campbell et al. 1988) due to central sensitization and altered connectivity in the spinal cord (Woolf et al. 1992) (Figure 2).”